| Objective:1.To determine the expression level of PAX1 gene m RNA in endometrial cancer tissue and normal endometrial tissue,and compare the difference in the expression of PAX1 gene m RNA in endometrial cancer and normal endometrial tissue;2.To explore the diagnostic significance of PAX1 gene promoter methylation in endometrial cancer by detecting the degree of PAX1 gene promoter methylation in endometrial cancer tissue and normal endometrial tissue;3.Collect postoperative pathological data of patients with endometrial cancer,and explore the relationship between PAX1 gene promoter methylation and postoperative pathological characteristics of patients with endometrial cancer;4.To detect the degree of methylation of the PAX1 gene promoter between the peripheral blood of endometrial cancer patients and the peripheral blood of normal endometrial patients,and to deeply discuss the diagnostic efficacy of peripheral blood methylation detection in endometrial cancer.Methods:A total of 36 patients with endometrial cancer(EC)who underwent comprehensive staging surgery in affiliated hospital of Jining medical college Gynecology Department from January 2021 to September 2022 were selected as the experimental group;Normal endometrial tissue was obtained from 36 patients who underwent surgical treatment for other gynecological diseases(such as uterine fibroids and adenomyosis)during the same period and were confirmed as normal endometrium by histopathology.They were divided into a normal control group(NC).Peripheral blood was obtained from 22 patients with EC and22 patients with NC before surgery.Real-time fluorescence quantitative PCR(q PCR)was used to detect the expression level of PAX1 gene m RNA in EC and NC tissues.Statistical methods were used to analyze the relationship between the degree of methylation of the PAX1 gene promoter and postoperative pathological characteristics in patients with endometrial cancer.DNA extraction,bisulfite modification,methylation specific PCR and agarose gel electrophoresis were used to detect the methylation degree of the promoter of PAX1 gene in EC tissue,NC tissue,peripheral blood of EC patients and peripheral blood of NC patients.Results:1.The expression level of PAX1 gene m RNA in endometrial cancer tissue is lower than that in normal endometrial tissue.2.The results of methylation detection showed that the positive rate of PAX1 gene promoter methylation in EC tissue was significantly higher than that in NC tissue(P<0.05).The sensitivity and specificity of PAX1 gene promoter methylation in tissue for detecting endometrial cancer were 83.33% and 44.44%,respectively.3.Analysis of the clinicopathological characteristics of patients with endometrial carcinoma showed that patients with FIGO stages II,III,and IV,patients with lymph node metastasis,and patients with non endometrial carcinoma had a higher positive rate of methylation,but there was no significant difference in the methylation of the PAX1 gene promoter among different pathological stages,whether there was lymph node metastasis,and different pathological types(P>0.05).4.The positive rate of PAX1 gene promoter methylation in peripheral blood of EC patients was significantly higher than that of NC patients,with a significant difference(P<0.05).The sensitivity and specificity of PAX1 gene methylation in peripheral blood for detecting endometrial cancer were 72.73% and 59.09%,respectively.Conclusion:1.Detection of PAX1 gene m RNA expression in EC and NC tissues using real-time fluorescence quantitative PCR showed that the expression of PAX1 gene was relatively low in endometrial cancer tissues,indicating that the low expression of PAX1 gene m RNA may be related to the occurrence of endometrial cancer.2.This study found that the positive rate of methylation of the PAX1 gene promoter in endometrial cancer tissue is higher than that in NC patients.The sensitivity and specificity of methylation of the PAX1 gene promoter region in the diagnosis of endometrial cancer are 83.33% and44.44%,respectively.Histologically,it was confirmed that methylation of the PAX1 gene promoter may have certain diagnostic value for endometrial cancer.3.Combined with clinical and pathological data,EC patients with FIGO stages II,III,and IV,EC patients with lymph node metastasis,and patients with non endometrioid carcinoma showed positive methylation of the PAX1 gene,further demonstrating that methylation of the PAX1 gene may be related to the progression and severity of endometrial carcinoma.4.In this study,methylation detection was performed in peripheral blood of patients with EC and NC,and there was a statistically significant difference in the positive rate of methylation in peripheral blood between the two groups(P<0.05).The sensitivity and specificity of PAX1 gene promoter methylation in the diagnosis of endometrial cancer were72.73% and 59.09%,respectively.Compared with the positive rate of PAX1 gene promoter methylation in peripheral blood of EC patients,the positive rate of PAX1 gene promoter methylation in EC tissue was higher,and the difference between the two was not statistically significant(P>0.05).Detection of peripheral blood methylation may provide a new idea for the diagnosis of endometrial cancer through less invasive methods in the future. |
PDF Full Text Request